ST工智(000584) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥268,201,821.49, a decrease of 30.17% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥31,973,551.38, representing a decline of 528.64% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥57,709,603.89, down 278.17% from the previous year[3]. - The basic earnings per share for the period was -¥0.0420, a decrease of 491.55% year-on-year[3]. - The weighted average return on equity was -1.37%, down 470.83% compared to the previous year[3]. - The company reported a net cash flow from operating activities of -¥152,734,289.33, a decline of 740.49% year-to-date[3]. - The company reported a significant decrease in cash and cash equivalents, with a net decrease of 115.86% to -¥37,451,256.31, attributed to reduced net inflow from financing activities[10]. - Net profit for the third quarter was a loss of CNY 93,911,155.04, compared to a loss of CNY 30,318,550.44 in the same period last year, indicating a significant increase in losses[32]. - The basic and diluted earnings per share were both reported at -0.1155, compared to -0.0445 in the previous year, reflecting worsening financial performance[33]. Assets and Liabilities - The total assets at the end of the reporting period were ¥5,456,123,608.97, an increase of 8.76% compared to the end of the previous year[3]. - The company's total assets reached CNY 5,456,123,608.97, up from CNY 5,016,498,223.62, marking an increase of approximately 8.8%[29]. - Total liabilities increased to CNY 2,998,700,985.01 from CNY 2,464,973,706.78, which is an increase of about 21.6%[29]. - The total equity attributable to shareholders decreased by 3.67% to ¥2,310,302,890.10 compared to the previous year[4]. - The total equity attributable to shareholders decreased to CNY 2,310,302,890.10 from CNY 2,398,315,591.61, a decline of approximately 3.7%[29]. Cash Flow - The cash inflow from operating activities was CNY 943,377,830.85, a decrease of 15.3% compared to CNY 1,113,437,935.96 in the previous period[36]. - The net cash flow from operating activities was CNY -152,734,289.33, compared to CNY 23,846,447.04 in the same period last year[36]. - The cash inflow from investment activities totaled CNY 262,240,035.90, significantly up from CNY 13,301,831.20 in the previous period[37]. - The net cash flow from investment activities was CNY -252,748,427.18, an improvement from CNY -330,791,115.84 in the previous year[37]. - The cash inflow from financing activities was CNY 744,839,620.83, down from CNY 1,060,541,727.57 in the previous period[37]. - The net cash flow from financing activities was CNY 372,594,600.32, compared to CNY 542,989,876.69 in the same period last year[37]. - The ending balance of cash and cash equivalents was CNY 249,513,322.44, down from CNY 460,688,444.22 in the previous year[37]. - The company received CNY 434,653,370.83 in cash from borrowings, an increase from CNY 363,841,688.05 in the previous period[37]. - The company paid CNY 283,351,849.94 in cash to repay debts, compared to CNY 184,672,764.45 in the previous year[37]. Investments and Acquisitions - The company invested CNY 54 million in Jiangsu Harbin Haidu Industrial Robot Co., Ltd. with a profit commitment of CNY 36 million for the period from 2018 to 2020, but failed to achieve 80% of this target[14]. - The company invested CNY 108 million in Harbin University of Technology Special Robots Co., Ltd. with a profit commitment of CNY 135 million for the same period, also failing to meet 80% of the target[16]. - The company invested CNY 36 million in Jiangsu Harbin Pharmaceutical Machinery Technology Co., Ltd. with a profit commitment of CNY 30 million, which was later extended to CNY 33 million due to the impact of COVID-19[17]. - The company transferred 5.0661% of its shares in Jiangsu Harbin Pharmaceutical Machinery Technology Co., Ltd. for CNY 10 million, reducing its stake from 22.2910% to 17.2249%[18]. - The company approved a share buyback plan with a total fund of CNY 30 million to CNY 60 million, with a maximum price of CNY 12.09 per share, and has repurchased 173,400 shares by September 30, 2021[19]. - The company relinquished its proportionate rights to increase capital in Shanghai Shixu Technology Co., Ltd. and transferred its entire stake for a total of CNY 24.884996 million[20]. - The company plans to terminate the "Industrial Robot Intelligent Equipment Manufacturing and AI Technology R&D and Industrialization Project" and repurpose the remaining fundraising of CNY 48,858.97 million, with CNY 27,518.24 million allocated for acquiring 70% of Jilin Jiangji Minke Industrial Co., Ltd. and CNY 21,340.73 million for R&D center construction[21]. - The acquisition of 70% equity in Jiangji Minke is priced at CNY 84,000.00 million, based on an evaluation of CNY 120,088.00 million as of December 31, 2020[23]. - The company has received regulatory approval for the acquisition of Jiangji Minke, with the antitrust review completed in July 2021[23]. Operational Highlights - The company experienced a 130.54% increase in prepayments, totaling ¥156,100,464.28, primarily due to advance payments for goods and construction[8]. - Sales expenses increased by 53.19% to ¥43,100,372.26, driven by the expansion of the robot business and sales channel development[9]. - Research and development expenses were CNY 59,047,172.58, slightly down from CNY 60,083,268.51, showing a minor reduction in investment in innovation[32]. - The company aims to enhance its core competitiveness by entering military optical products and equipment sectors, leveraging its strengths in high-end intelligent manufacturing[23]. - The company has initiated a lawsuit compensation agreement to mitigate potential losses from litigation involving its subsidiary Zhejiang Ruifeng Electromechanical Co., Ltd.[24]. - The company intends to purchase liability insurance for its directors and senior management, with a maximum annual premium of CNY 600,000 and a compensation limit of CNY 100,000,000[25]. Other Financial Metrics - The company recognized non-recurring gains of ¥25,736,052.51 for the reporting period[6]. - The company reported a 231.17% increase in investment income, amounting to ¥12,068,266.78, due to gains from the disposal of long-term equity investments[9]. - Short-term borrowings increased by 44.44% to ¥500,821,045.25, reflecting a rise in short-term bank loans during the reporting period[9]. - The deferred income tax assets surged by 123.07% to ¥58,876,539.06, primarily due to an increase in unabsorbed losses[9]. - The company reported a significant increase in other income to CNY 12,250,804.28 from CNY 63,017,651.64, indicating fluctuations in non-operating income sources[32].